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Hepatitis C Virus Mediated Changes in miRNA-449a
Modulates Inflammatory Biomarker YKL40 through
Components of the NOTCH Signaling Pathway
Nayan J. Sarma1, Venkataswarup Tiriveedhi1, Vijay Subramanian1, Surendra Shenoy1, Jeffrey S. Crippin3,
William C. Chapman1, Thalachallour Mohanakumar1,2*
1 Department of Surgery, Washington University School of Medicine, Saint Louis, Missouri, United States of America, 2 Department of Pathology & Immunology,
Washington University School of Medicine, Saint Louis, Missouri, United States of America, 3 Department of Medicine, Washington University School of Medicine, Saint
Louis, Missouri, United States of America

Abstract
Liver disease due to hepatitis C virus (HCV) infection is an important health problem worldwide. HCV induced changes in
microRNAs (miRNA) are shown to mediate inflammation leading to liver fibrosis. Gene expression analyses identified
dysregulation of miRNA-449a in HCV patients but not in alcoholic and non-alcoholic liver diseases. By sequence analysis of
the promoter for YKL40, an inflammatory marker upregulated in patients with chronic liver diseases with fibrosis, adjacent
binding sites for nuclear factor of Kappa B/P65 and CCAAT/enhancer-binding protein alpha (CEBPa) were identified. P65
interacted with CEBPa to co-operatively activate YKL40 expression through sequence specific DNA binding. In vitro analysis
demonstrated that tumor necrosis factor alpha (TNFa) mediated YKL40 expression is regulated by miRNA-449a and its target
NOTCH1 in human hepatocytes.NOTCH1 facilitated nuclear localization of P65 in response to TNFa. Further, HCV patients
demonstrated upregulation of NOTCH1 along with downregulation of miRNA-449a. Taken together it is demonstrated that
miRNA-449a plays an important role in modulating expression of YKL40 through targeting the components of the NOTCH
signaling pathway following HCV infection. Therefore, defining transcriptional regulatory mechanisms which control
inflammatory responses and fibrosis will be important towards developing strategies to prevent hepatic fibrosis especially
following HCV recurrence in liver transplant recipients.
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is a multimeric DNA binding transcription factor involved in
inflammatory and immune disorders especially autoimmune
diseases and cancer [10]. NOTCH1 is one of the upstream
regulator of NFKB complex and downregulation of NOTCH1
impairs its function [11,12]. It has been shown that NOTCH1 and
TNFa regulate nuclear retention of NFKB [13,14]. CCAAT/
enhancer-binding protein alpha (CEBPa) is a homodimeric DNA
binding bZIP transcription factor that controls cell proliferation
and differentiation [15]. CEBPa is differentially regulated in cases
of HCC and targets expression of a wide range of genes and
microRNAs (miRNA) involved in liver diseases [16,17].
miRNAs have been shown to play an important role in immune
evasion, regulation of cell cycle and in cancer progression
[18,19,20]. HCV infection results in modulation of miRNA
particularly those that control viral particle entry and propagation,
thus playing an important role in host immune evasion [21]. In
this study we defined the molecular mechanisms of YKL40
expression that involves HCV induced miRNA modulation and
regulation by novel pathways including NOTCH1, NFKB and
CEBPa.

Introduction
Liver diseases resulting from hepatitis C virus (HCV) infection is
a major health issue worldwide as well as the United States [1,2].
It is estimated that about 4 million people are infected with HCV
in the United States and about 300 million worldwide [1]. The
natural history of HCV infection in the liver is characterized by
slow progression to fibrosis and cirrhosis, end-stage liver diseases,
and high risk of developing hepatocellular carcinoma (HCC) [3].
YKL40 (CHI3L1) is a member of the ‘‘mammalian chitinase–
like proteins,’’ secreted by activated macrophages and neutrophils
during inflammation in various tissues including liver, smooth
muscle and cancer cells [4]. YKL40 is elevated in patients with
chronic liver diseases that are characterized by inflammation and
increased extra-cellular remodeling [5,6]. Although increased
levels of YKL40 have been shown to be induced by tumor
necrosis factor alpha (TNFa), the molecular mechanisms are not
clearly identified [7]. TNFa, an inflammatory cytokine regulates
gene expression in the nuclear factor of Kappa B (NFKB) signaling
pathway [8]. Components of the mammalian NFKB family of
transcription factors includes NFKB1 (P105/P50), NFKB2 (P100/
P52), RelA (P65), RelB and c-Rel [9]. The NFKB component P65
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assays and TaqManH Universal Master Mix II (Life technologies,
NY) using predesigned primers. Quantitative PCR (qPCR) to
analyze YKL40 and NOTCH1 was performed using a BioRad
Real-Time PCR System with cycling conditions of 95uC for
10 min followed by 95uC for 15 sec and 60uC for 60 sec for a total
of 40 cycles. Each TaqMan assay was run in triplicate. The DDCt
value was calculated by normalizing the threshold (CT) values
with GAPDH expression and respective gene expression in
controls.

Table 1. Patient Demographics.

Demographic

HCV

Number (n)

10

10

10

10

Age (mean, SD)

5764

5067

5465

34613

Gender M:F
Recipient Race (n)

Caucasian

African American

AH

NASH

Control

6:4

5:5

7:3

5:5

5

4

5

5

5

5

5

5

1.860.6

0.960.8

Others

Primary Hepatocytes and HEPG2 Cell Line Transfection

1

Bilirubin (mg/dL)

1.960.4

1.560.3

AST (IU/ml)

90634

110640 74630

25610

ALT (IU/ml)

55629

140660 63638

23612

HCV Viral load (X106/mL)

1.460.3

n/a

n/a

n/a

HCV genotype

1

4

n/a

n/a

n/a

%

21.5%

n/a

n/a

n/a

1a

4

n/a

n/a

n/a

%

30.8%

n/a

n/a

n/a

1b

2

n/a

n/a

n/a

%

15.4%

n/a

n/a

n/a

Primary human hepatocytes were purchased from Life Technologies, New York and grown in 24 well plates in Williams
Medium E supplemented with 5% FCS, 100 units/mL penicillin,
100 units/ml Amphotericin, 0.1% Albumin, 300 nM insulin,
2 mM L-glutamine and 0.1 nM Hydrocortisone. HEPG2 cells
were grown in RPMI with 10% FBS, 1 mM sodium-pyruvate,
10 mM HEPES, 2 mM L-glutamine, and 100 units/mL penicillin/streptomycin. 20 ng/ml of TNFa (Sigma, St. Louis, MO) was
added for 6 hours wherever indicated. The optimal concentration
of TNFa was determined by dose-dependent analyses.
For transfection of hepatocytes and HEPG2 cells (ATCC),
0.26105 cells were seeded into each well of a 24 well plate and
grown for 24–48 hours. On the day of transfection, medium was
changed and 500 ng of DNA was transfected using LipofectamineTM LTX and Plus Reagent (Invitrogen, NY). For siRNA
delivery 0.16105 cells were grown in each well of a 24 well plate
for 24–48 hours in antibiotic free medium and 80 pico moles of
siRNA were transfected using LipofectamineTM RNAiMAX
(Invitrogen). Cells were harvested 48 hours post transfection and
efficiency was measured by qPCR, immunostaining and western
blot.

SD: Standard Deviation, HCV: Hepatitis C Virus, AH: Alcoholic Hepatitis, NASH:
Non-Alcoholic Steatohepatitis, M: Male, F: Female, AST: Aspartate Amino
Transferase, ALT: Alanine Amino Transferase.
doi:10.1371/journal.pone.0050826.t001

Materials and Methods
Patients
Liver biopsies were obtained from 10 chronic HCV patients, 10
alcoholic hepatitis patients, 10 non-alcoholic steatohepatitis
patients and 10 normal donor livers (control) at the time of
transplantation at Washington University Medical Center/BarnesJewish Hospital (Table 1). Patients with hepatitis B virus and/or
HIV were excluded from the study. All of the human studies were
approved by the human research protection committee at
Washington University (protocol 201104075) and patients were
enrolled after written informed consent was obtained.

Western Blot and Immunofluorescence Microscopy
For localization of YKL40, NOTCH1 and P65, 50,000 HEPG2
cells were grown on coverslips in 24 well plates. Immunostaining
was done as described before [22]. Briefly, cells were fixed with
4% paraformaldehyde and permeabilized with 0.1% Triton X100. 2% normal goat serum in DPBS with 1% BSA, 0.1% Tween
20 was used for blocking and washing. Primary antibodies for
western blot and Immunofluorescence used were goat anti-YKL40
(sc-31722), rabbit anti-NOTCH1 (sc-9170), mouse anti-CEBPa
(sc-166258) and rabbit anti-P65 (sc-109). The secondary antibodies
used were FITC-conjugated anti-mouse IgG (sc-2010), Rhodamine-conjugated anti-goat IgG (sc-3945) and Rhodamine-conjugated anti-rabbit IgG (sc-2492). The images were captured using
an Eclipse 80i fluorescent microscope (Nikon, NY) and processed
using Metamorph version 6.3r2 software (Molecular Devices, CA).
Extraction of the nuclear and cytoplasmic fractions from the
hepatocytes (16106 cells) was done using NE-PERH Nuclear and
Cytoplasmic Extraction Kit (Thermo Scientific, IL).

Plasmids and Constructs
For YKL40 luciferase constructs, the promoter regions were
amplified from human genomic DNA (Zyagen, CA) by PCR using
iProof High-Fidelity DNA Polymerase (Biorad, CA). PCR
products were subcloned into pGL4.11 vector (Promega, WI)
upstream of a luciferase gene using the NheI/EcoRV restriction
sites. P65 and CEBPa were amplified from a human cDNA library
(Stratagene, CA) and subcloned into pcDNA using the HindIII/
Not1 and HindIII/BamH1 restriction sites, respectively. HsamiRNA-449a (SC400399) and control constructs were purchased
from Origene, MD. NOTCH1 (sc-36095), P65 (sc-29410) and
control siRNA (sc-37007) were purchased from Santacruz Biotechnology, CA. Computational analysis of the promoter bound
transcription factors was done using the Transcription Element
Search System http://www.cbil.upenn.edu/cgi-bin/tess/tess.
miRNA target analysis was done using http://www.targetscan.
org.

Luciferase Assay
Human primary hepatocytes (16105) were transfected in 24
well plates as mentioned earlier with 1 mg pGL4.11 luciferase
reporter vector or pGL4.11 driven by the YKL40 promoter or
deletion constructs. For miRNA regulation studies the reporter
construct was transfected in combination with 1 mg of either
control vector or vector expressing miRNA-449 precursor. For
NOTCH1 regulation studies the reporter construct was transfected
in combination with 80 picomoles of either non specific siRNA or
siRNA specific for NOTCH1. For transcription factor studies the
reporter constructs were transfected in combination with 2 mg of
empty pcDNA3 vector, or pcDNA3 expressing P65 or CEBPa or

miRNA and mRNA Expression Analysis
Total RNA was isolated from the liver biopsies or hepatocytes
using the RNAaqueous kit (Ambion, NY). Expression level of
miRNA-449a was determined using the TaqManH MicroRNA
PLOS ONE | www.plosone.org
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Figure 1. miRNA-449a is downregulated in HCV patients and YKL40 is upregulated in patients with hepatic fibrosis. Total RNA was
isolated from liver biopsies obtained from 10 chronic HCV patients, 10 alcoholic hepatitis patients, 10 non-alcoholic steatohepatitis (NASH) patients
and 10 normal donor livers (control). Expression of miRNA-449a (1A) and YKL40 (1B) were determined by Q-PCR. The DDCt value was calculated by
normalizing the threshold (CT) values with GAPDH expression and miRNA-449a (1A) or YKL40 (1B) expression respectively in controls. The ‘*’
represents p value,0.01 obtained by a two-tailed t test. Error bars represent Standard Deviations (SD) calculated from three independent
experiments.
doi:10.1371/journal.pone.0050826.g001

both. 20 ng/ml of TNFa was added to the medium 6 hours before
harvesting. To control for efficiency of transfection, 0.1 mg of
pRL-TK (Promega, Madison, WI), which expresses Renilla
luciferase was included. Luciferase activity was measured 48 h
after electroporation using the Dual Luciferase Reporter Assay
System (Promega, Madison, WI) and the results were normalized
to Renilla luciferase.

CEBPa were detected with a rabbit anti-P65 or a mouse antiCEBPa respectively.

Chromatin Immunoprecipitation
Chromatin Immunoprecipitation was carried out with ChIPITTM Express (Active Motif, Carlsbad, CA). Briefly, hepatocytes
(16106) were crosslinked with 1% formaldehyde and quenched
with 0.375 M glycine. Nuclei were isolated and sonicated in
350 ml of shearing buffer to prepare chromatin extracts. 1 mg of
antibodies for control IgG, P65 or CEBPa were added to 60 ml of
sheared chromatin along with Protein G Magnetic Beads.
Antibody-lysate mix was washed and DNA was eluted according
to the instructions. YKL40 promoter regions were amplified by
PCR.

Co-immunoprecipitation
Immunoprecipitation of P65 with CEBPa or the reverse
immunoprecipiation in TNFa treated hepatocytes (16106) were
carried out as described by Sarma et al [22]. Briefly, cells were
washed with DPBS, and lysed with 0.5 ml of lysis buffer (10 mM
Tris-HCl, pH 7.5, 0.4 M NaCl, 1% Nonidet P-40, 0.4% Triton
X-100, 0.2% sodium deoxycholate, 1 mM EDTA, protease
inhibitors (PI), 1 mM PMSF). Diluted with 0.5 ml buffer containing 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, PI, 1 mM PMSF
and centrifuged at 17,0006g for 30 min. 1 mg normal mouse/
rabbit IgG or mouse anti-CEBPa or rabbit anti-P65 was used to
immunoprecipitate the complexes from the supernatant. After
overnight incubation with the antibodies 30 ml of Protein G beads
were added to lysates and incubated for another 1 hour. Beads
were washed with 700 ml of wash buffer (10 mM Tris-HCl,
pH 7.5, 0.2 M NaCl, 0.5% Nonidet P-40, 0.2% Triton X-100,
0.1% sodium deoxycholate, 1 mM EDTA, PI, 1 mM PMSF)
3 min each for 5 times and once with cold DPBS by centrifugation
at 1,8006g for 3 min at 4uC. Immunocomplexes were eluted by
boiling with 30 ml of 2X SDS buffer (0.1 M Tris-HCl, pH 6.8,
3.5% SDS, 10% glycerol, 2 mM DTT, 0.004% bromphenol blue)
for 10 min and subjected to SDS-PAGE (4–20% gel). P65 or
PLOS ONE | www.plosone.org

Results
miRNA-449a is Downregulated in HCV Patients
A genomewide miRNA analysis in liver biopsies obtained from
chronic HCV infected patients demonstrated a distinct expression
profile when compared to the normal liver. Particularly, a significant downregulation of microRNA-449a was observed in the
HCV infected livers.
To analyze the specific role of miRNA-449a following HCV
infection, biopsies were obtained from 10 chronic HCV patients,
10 alcoholic hepatitis patients, 10 non-alcoholic Steatohepatitis
(NASH) patients and 10 control normal donor livers at the time of
liver transplant. Total RNA was isolated from the liver biopsies
and expression level of miRNA-449a was determined by qPCR
using specific primers and the results were normalized to GAPDH
3
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Figure 2. TNFa regulates the expression of YKL40 at the transcriptional level. A. (Upper panel) Hepatocytes were transfected with an
23000 bp YKL40-promoter driven reporter construct with (+) or without (2) TNFa. Firefly luciferase activity was measured 48 hours after transfection
and normalized to a Renilla luciferase internal control. The numbers represent fold-change over control (average of three independent experiments);
error bars represent SD. The ‘*’ represents p value,0.05 obtained by a two-tailed t test. (Lower panel): hepatocytes from 2A were immunoblotted with
anti-YKL40 with (+) or without (2) TNFa. ACTIN was used as the loading control. B. HEPG2 cells were immunostained with anti-YKL40 antibody
without (2) or with (+) TNFa. C. Quantification of the YKL40 immunostaining signal in HEPG2 cells (1B). The numbers represent the average
fluorescence intensity of YKL40 (n = 100). D. Essential regions in the YKL40 promoter required for TNFa mediated expression. Hepatocytes were
transfected with luciferase reporters driven by deletion constructs of YKL40 promoter (23000 bp, 22000 bp, 21000 bp, 2500 bp, filled black bars
on left) construct with (+) or without (2) TNFa. Firefly luciferase activity was measured 48 hours after transfection and normalized to a Renilla
luciferase internal control. The luciferase activity was normalized to the control empty luciferase vector and the numbers represent fold-change over
control (average of three independent experiments); error bars represent SD calculated from three independent experiments.
doi:10.1371/journal.pone.0050826.g002

expression. Expression analysis demonstrated that miRNA-449a is
downregulated more than two fold in livers obtained from HCV

PLOS ONE | www.plosone.org

patients whereas no significant differences in the expression was
observed in alcoholic hepatitis patients, NASH patients and
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Figure 3. Transcription factors P65 and CEBPa regulate expression of YKL40. A. Computational prediction of transcription factors binding to
the YKL40 promoter. Computational analysis of 24000 bp upstream of the open reading frame using the Transcription Element Search System (TESS).
The bars represent the predicted consensus binding sites in the DNA for transcription factors P65 and CEBPa. B. Mutation of NFKB/P65 binding site
inhibits TNFa mediated YKL40 induction. Hepatocytes were transfected with luciferase reporters driven by deletion constructs of YKL40 promoter
2578 bp wildtype, 2578 bp P65 binding site mutated (*) and 2500 bp wildtype (P65 site deleted), filled black bars on left) construct with (+) or
without (2) TNFa. Firefly luciferase activity was measured 48 hours after transfection and normalized to a Renilla luciferase internal control. The
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numbers represent fold-change over the 2578 wildtype construct without TNFa treatment (average of three independent experiments); error bars
represent SD. The P65 binding site mutation is shown in the lower panel. The ‘*’ represents p value ,0.05 obtained by a two-tailed t test. C. CEBPa in
an upstream transcription factor to activate YKL40 expression. Hepatocytes were transfected with luciferase reporters driven by deletion constructs of
YKL40 promoter (23000 bp, 22000 bp, 21000 bp, 2500 bp, filled black bars on left) along with an empty vector or vector expressing CEBPa and
treated with TNFa. Firefly luciferase activity was measured 48 hours after transfection and normalized to a Renilla luciferase internal control. The
numbers represent fold-change over the control empty luciferase vector (average of three independent experiments); error bars represent SD.
doi:10.1371/journal.pone.0050826.g003

measured. Significant increases (.10 fold) in the expression from
the YKL40 promoter deletion constructs were observed in the cells
treated with TNFa compared to untreated (Figure 2D). However,
deletion of the 21000 to 2500 bp region of the YKL40 promoter
impaired TNFa mediated transcriptional induction. This indicates
that this region (21000 to 2500 bp) contains binding sites for
transcriptional regulatory elements on the YKL40 promoter.

normal livers (Figure 1A). This suggests that miRNA-449a is
specifically downreguated in patients with liver diseases following
HCV infection.

YKL40 is Upregulated in HCV Patients with Fibrosis
To determine the expression level of YKL40 in liver diseases,
biopsies were obtained from 10 chronic HCV patients, 10
alcoholic hepatitis patients, 10 NASH patients and 10 control
normal donor livers at the time of liver transplant. Total RNA was
isolated from the liver biopsies and expression level of YKL40 was
determined by qPCR using specific primers and the results were
normalized to GAPDH expression. Expression analysis showed that
YKL40 to be upregulated in alcoholic hepatitis patients (2.4 fold),
NASH patients (2.9 fold) and HCV patients (2.6 fold) compared to
normals (Figure 1B). These results demonstrate that YKL40 is
elevated in patients with chronic liver diseases which are
accompanied by inflammation.

Computational Prediction of Transcription Factors
Regulating YKL40 Expression
In order to identify transcription factors that regulate the
expression of YKL40 a computational analysis of 24000 bp
upstream of the open reading frame was done using the
transcription element search system. The program predicted
consensus binding sites in the DNA for several transcription factors
that included NFKB subunit P65 and CEBPa (Figure 3A). The
software predicted a consensus binding site for p65
(GGAATTTCC) at 2578 bp position at the promoter. Similarly
several DNA binding sites for CEBPa (CCAAT) was also
predicted throughout the YKL40 promoter. Most of the CEBPa
binding sites were concentrated in the 23000 to 22000 bp region
of the promoter. Interestingly, two CEBPa binding sites were
identified in close proximity to the P65 DNA binding site on the
promoter (Figure 3A) suggesting that these two transcription
factors may bind to the YKL40 promoter by forming a transcriptional regulatory complex.

TNFa Regulates the Expression of YKL40 at the
Transcriptional Level
We and others have shown that YKL40 expression is elevated in
patients with chronic liver diseases accompanied by inflammation
[5,6]. In vitro studies have shown that inflammatory cytokines such
as TNFa have the ability to induce expression of YKL40 [7]. To
study the molecular mechanisms of TNFa mediated regulation of
YKL40, 23000 base pairs (bp) of the human YKL40 promoter was
cloned upstream of a luciferase reporter gene and the construct
was introduced into human hepatocytes. The cells were treated
either with or without 20 ng/ml TNFa for 6 hours and luciferase
activity was measured. More than four fold increase in the YKL40
promoter activity was observed in cells treated with TNFa
compared to untreated (Figure 2A, upper panel). Further, western
blot analysis showed increased expression of YKL40 in TNFa
treated cells (Figure 2A, lower panel). This reporter gene analysis
suggests that TNFa regulates the expression of YKL40 through
modulation of upstream transcriptional complexes that interact
with the YKL40 promoter.
To further demonstrate that TNFa induces expression of
YKL40, human HEPG2 cells were cultured and treated with
TNFa. Immunostaining of the HEPG2 cells with anti-YKL40
showed a more than 2 fold increase in expression of YKL40 in the
cells treated with TNFa compared to untreated cells (Figures 2B
and 2C).

Mutation of NFKB (P65) Binding Site Inhibits TNFa
Mediated YKL40 Induction
Computational analysis predicted a putative binding site for
NFKB subunit P65 at 2578 bp position of the human YKL40
promoter. Further the YKL40 promoter analysis using the deletion
constructs identified 21000 to 2500 bp region to be essential for
TNFa mediated induction of YKL40 in hepatocytes. To test
whether P65 binding plays a role in TNFa mediated upregulation
of YKL40 promoter a 2578 bp wildtype luciferase reporter
construct, a 2578 bp construct with point mutations in the P65
binding site (wildtype: GGAATTTCC, point mutation: AGCTTATCA) and a 2500 bp construct with P65 binding site deleted
were prepared. Hepatocytes were transfected with these three
reporter constructs and cells were treated either with or without
TNFa and Luciferase activity was measured. As expected the
wildtype 2578 bp promoter construct with an intact P65 binding
site showed two fold increase in transcriptional activity in the
presence of TNFa (Figure 3B). However, point mutation in the
P65 binding site or deletion of the P65 binding site (2500 bp)
completely abolished TNFa mediated induction of YKL40
(Figure 3B). Further, we demonstrated that siRNA mediated
knockdown of P65 resulted in impairment of transcriptional
activation by the YKL40 promoter in TNFa treated cells.

Reporter Analysis Identified Essential Regions in the
YKL40 Promoter Required for TNFa Regulated Expression
of YKL40
Since TNFa regulated the expression of YKL40 at the
transcriptional level we hypothesized the possible interaction of
TNFa with upstream regulatory complexes of the YKL40 gene. To
identify the essential regions for TNFa mediated expression
deletion mutants of the YKL40 promoter regions were cloned
upstream of a luciferase reporter gene. Sequential deletion
mutants of the YKL40 promoter region (Figure 2D, black filled
bars on the left) were introduced into hepatocytes. The cells were
treated with or without TNFa and the luciferase activity was
PLOS ONE | www.plosone.org

CEBPa in an Upstream Transcription Factor which
Activate YKL40 Expression
Computational analysis identified CEBPa as a putative DNA
binding factor for transcriptional regulation of YKL40. To test
whether CEBPa regulates YKL40 expression an empty vector or
6
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Figure 4. CEBPa interacts with NFKB/P65 to bind YKL40 promoter and cooperates to activate transcription in hepatocytes. A. YKL40
promoter showing binding sites for P65 and CEBPa. The black horizontal bars represent regions amplified by the PCR primers. B. Chromatin was
immunoprecipitated with anti-P65 or anti-CEBPa or isotype control IgG from hepatocytes. Segments of the YKL40 promoter (indicated in 4A) were
amplified by PCR. The first three lanes show immunoprecipitated chromatin (IP) and the fourth lane show input chromatin (Input). ACTIN promoter
amplification is shown as the negative control. C. Co-immunoprecipitation of P65 with CEBPa in hepatocytes. Whole cell lysates were subjected to
immunoprecipitation with either rabbit IgG or anti-P65. CEBPa in the cell lysates (Input) and immunoprecipitated complexes (IP) was detected by
immunoblotting with anti-CEBPa. P65 was detected by immunoblotting with anti-P65. D. HEPG2 cells were treated with (+) or without (2) TNFa and
co-immunostained with anti-CEBPa and anti-P65. E. Hepatocytes were transfected with a luciferase construct driven by the 23000 bp YKL40
promoter in addition to the control vector or vector expressing P65 or CEBPa or both. Firefly luciferase activity was measured 48 hours after
transfection and normalized to a Renilla luciferase internal control. The numbers represent fold-change over the control empty vector (average of
three independent experiments); error bars represent SD. Bottom panel, expression of P65 and CEBPa was verified by immunoblotting with anti-P65
and anti-CEBPa respectively.
doi:10.1371/journal.pone.0050826.g004

a vector expressing CEBPa was overexpressed in hepatocytes
along with deletion mutants of the YKL40 promoter cloned
upstream of a luciferase reporter gene. The deletion mutants
included 23000 bp, 22000 bp, 21000 bp and 2500 bp of the
YKL40 promoter region (Figure 3C, black filled bars on the left)
and the luciferase activity was measured after the cells were treated
with TNFa for 6 hours. Significant increases (.9 fold) in the
YKL40 expression from the 23000 bp promoter construct was
noted when CEBPa was overexpressed compared to control
empty vector (Figure 3C). However, deletion of the 23000 bp to
22000 bp region of the YKL40 promoter impaired CEBPa
mediated transcriptional induction of YKL40 as that region
contained several putative CEBPa binding sites as shown on our
computational analysis (Figure 3A).

immunoblotting with anti-P65 (Figure S1). To further demonstrate
the interaction between P65 and CEBPa, HEPG2 cells were
treated with or without TNFa and co-immunostained with antiCEBPa and anti-P65. CEBPa primarily localized to the nucleus in
both TNFa treated and untreated cells. P65 remained exclusively
cytoplasmic in the untreated cells with little to no nuclear
localization. In the TNFa treated cells, a significant amount of
P65 translocated into the nucleus and co-localized with CEBPa
(Figure 4D).
Immunoprecipitation and co-localization analyses indicated
that both P65 and CEBPa interact with each other and bind to
their consensus sites on the YKL40 promoter. To determine their
role in transcriptional regulation from the YKL40 promoter,
hepatocytes were co-transfected with a luciferase reporter
construct driven by the YKL40 promoter (23000 bp) with P65
or CEBPa or both. Overexpression of both P65 and CEBPa
resulted in significant increase in transcriptional activation of the
reporter construct compared to either alone (Figure 4E, upper
panel). Immunoblotting of the cell lysates with anti-P65 and antiCEBPa confirmed the elevated expression levels of these factors
compared to endogenous levels (Figure 4E, lower panel). This
demonstrates that CEBPa cooperates with NFKB to regulate
expression from the YKL40 promoter.

CEBPa Interacts with NFKB/P65 to Bind YKL40 Promoter
and Cooperates to Activate Transcription in Hepatocytes
Reporter analysis demonstrated that both P65 and CEBPa
regulate expression from the YKL40 promoter. To test whether
P65 and CEBPa interact and bind to adjacent consensus sites
present on the YKL40 promoter a chromatin immunoprecipitation
analysis was done. TNFa treated hepatocytes were fixed with
formaldehyde and chromatin extracts were prepared. The DNAprotein complexes were immunoprecipitated with anti-P65 or
anti-CEBPa or isotype control IgGs. Chromatin fragments were
isolated from the immunoprecipitated DNA-protein complexes
and subjected to PCR amplification using primers specific for
YKL40 promoter regions as shown in Figure 4A. The PCR
products were resolved on agarose gel. Chromatin immunoprecipitation analysis showed that both P65 and CEBPa bind to the
YKL40 promoter (Figure 4B). P65 binds to the 2300 bp to
2700 bp region of the YKL40 whereas no binding was observed
with other regions of the promoter. This region encompasses the
P65 binding site at 2578 bp position. CEPBa showed binding to
several regions of the YKL40 promoter where maximum band
intensity was seen at 21900 bp to 22300 bp region that
encompasses most of the CEBPa binding sites. Immunoprecipitation with isotype IgGs did not enrich any of these YKL40
promoter regions demonstrating the specificity for P65 or CEBPa.
No amplification of DNA was observed in PCR reactions
performed with primers specific for ACTIN promoter.
Binding of both CEBPa and P65 to the YKL40 promoter in
adjacent DNA binding sites suggests the possibility that they
interact with each other. To test this, crude lysates from TNFa
treated hepatocytes were prepared and subjected to immunoprecipitation with either isotype control IgG or anti-P65 followed by
immunoblotting with anti-CEBPa. CEBPa was co-immunoprecipitated with endogenous P65 whereas no CEBPa was observed
with the control IgG (Figure 4C). To confirm the interaction
a reverse co-immunoprecipitaion was done by immunoprecipitation with either isotype control IgG or anti-CEBPa followed by
PLOS ONE | www.plosone.org

NOTCH1 Regulates Nuclear Retention of NFKB/P65 in
Response to TNFa
Results presented clearly demonstrates that TNFa mediated
regulation of YKL40 is dependent on the NFKB subunit P65. To
demonstrate nuclear translocation of P65 in response to TNFa in
hepatocytes, cells were treated with or without TNFa and
cytoplasmic and nuclear extracts were prepared. Whole cell
lysates, the cytoplasmic fraction and the nuclear fraction were
subjected to immunoblotting with anti-P65. The expression of P65
was not affected by TNFa as no difference was observed in the
whole cell lysate (Figure 5A, left panel). However, significant
cytoplasmic exclusion and nuclear enrichment of P65 was
observed in TNFa treated cells compared to untreated cells.
One of the essential upstream regulators of NFKB complex is
NOTCH1 [11,12]. To analyze the role of NOTCH1, an upstream
factor required for TNFa mediated nuclear localization of P65,
and its functionality in facilitating downstream gene regulation,
hepatocytes were transfected either with scrambled siRNA or
siRNA specific for human NOTCH1 and subjected to TNFa
treatment. The siRNA mediated knockdown of NOTCH1 was
confirmed by immunoblotting with anti-Notch1 (Figure S2A).
Immunoblot using anti-P65 demonstrated that knockdown of
NOTCH1 resulted in impairment of TNFa mediated cytoplasmic
exclusion and nuclear translocation of P65 (Figure 5A, right
panel).
To further demonstrate that NOTCH1 is required for TNFa
mediated translocation of P65, HEPG2 cells were treated with or
8
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Figure 5. Notch1 regulates nuclear retention of NFKB/P65 in response to TNFa. A. (Right panel) Hepatocytes were treated with (+) or
without (2) TNFa and cytoplasmic and nuclear fractions were extracted. (Left panel) hepatocytes were transfected with either non-specific siRNA or
siRNA specific for NOTCH1 and treated with TNFa and cytoplasmic and nuclear fractions were extracted. Whole cell lysates, cytoplasmic and nuclear
extracts were subjected to immunoblotting with anti-P65. B. HEPG2 cells were treated with (+) or without (2) TNFa and immunostained with antiP65. The arrows indicate nuclear localization of P65. C. Quantification of the P65 immunostaining signal in HEPG2 cells (5B). The numbers represent
the average fluorescence intensity of P65 (n = 100). D. HEPG2 cells were transfected with either non-specific siRNA or siRNA specific for NOTCH1 and
treated with TNFa. The arrows indicate nuclear localization of P65. E. Quantification of the P65 immunostaining signal in HEPG2 cells (5D). The
numbers represent the average fluorescence intensity of P65 (n = 100). The ‘*’ represents p value,0.05 obtained by a two-tailed t test.
doi:10.1371/journal.pone.0050826.g005

without TNFa and probed for P65 localization by immunostaining
with anti-P65 (Figure 5B). In the untreated cells P65 remained

exclusively cytoplasmic with little to no nuclear localization
observed. In the TNFa treated cells, a significant amount of P65

Figure 6. microRNA 449a regulates YKL40 expression by targeting NOTCH1 for silencing. A & B. Hepatocytes were transfected with an
empty vector (2) or vector expressing miRNA-449a (+) and expression of NOTCH1 (6A) and miRNA-449a (6B) were determined by Q-PCR. The DDCT
value was calculated by normalizing the threshold (CT) values with GAPDH and expression of NOTCH1 and miRNA-449a respectively in controls. The ‘*’
represents p value,0.05 obtained by a two-tailed t test. C. (Upper panel) hepatocytes were transfected with a luciferase construct driven by the YKL40
promoter in addition to the control vector or vector expressing miRNA-449a or non-specific siRNA or siRNA specific for NOTCH1 or siRNA specific for
P65 in the presence of TNFa. Firefly luciferase activity was measured 48 hours after transfection and normalized to a Renilla luciferase internal control.
The numbers represent fold-change over the control vector (average of three independent experiments); error bars represent SD. (Lower panel)
Downregulation of YKL40, NOTCH1 and P65 is verified by immunoblotting with anti-YKL40 or anti-NOTCH1 or anti-P65 respectively. ACTIN is shown
as the loading control. D. Hepatocytes were transfected with a luciferase construct driven by the YKL40 promoter in addition to the control vector or
vector expressing miRNA-449a construct with (+) or without (2) TNFa. Firefly luciferase activity was measured 48 hours after transfection and
normalized to a Renilla luciferase internal control. The numbers represent fold-change over the control vector without TNFa (average of three
independent experiments); error bars represent SD. The ‘*’ represents p value,0.01 obtained by a two-tailed t test.
doi:10.1371/journal.pone.0050826.g006
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Figure 8. Schematic representation of HCV mediated role of
miRNA-449a in YKL40 expression. HCV infection results in downregulation of miRNA-449a that leads to upregulation of NOTCH1
eventually results in nuclear stabilization of P65. P65 upregulates YKL40
expression in co-operation with CEBPa in response to TNFa.
doi:10.1371/journal.pone.0050826.g008

empty vector of vector expressing miRNA-449a and expression of
both miRNA-449a and NOTCH1 were determined by qPCR.
The results were normalized to GAPDH expression. Increased
expression of miRNA-449a resulted in more than two fold
downregulation of NOTCH1 (Figure 6A and B).
Earlier we have shown that NFKB component P65, a protein
regulated by NOTCH1, activates YKL40 expression through
sequence specific promoter interaction (Figures 3 and 4). It is likely
that downregulation of miRNA-449a in HCV infected patients
(Figure 1A) results in activation of NOTCH1/NFKB signaling
that leads to upregulation of YKL40 expression. To test whether
miRNA-449a regulates YKL40 expression, hepatocytes were
transfected with either a control vector or vector expressing
miRNA-449a along with an YKL40 promoter-driven luciferase
reporter construct. In TNFa treated cells expression of YKL40 is
reduced by more than two fold in the presence of miRNA-449a
(Figure 6C, upper panel). qPCR analysis also showed downregulation of YKL40 by increased expression of miRNA-449a
(Figure S3).
Since, computational target analysis did not identify YKL40 to
be a direct target for miRNA-449a; results obtained from
promoter based reporter analysis suggest that miRNA-449a
regulates the expression of YKL40 by silencing components of
upstream transcriptional regulatory complexes such as
NOTCH1/NFKB. To demonstrate that downregulation of
YKL40 expression by miRNA-449a is mediated by silencing
NOTCH1, hepatocytes were transfected with either scrambled
siRNA or siRNA specific for NOTCH1 along with an YKL40driven luciferase reporter construct and cells were treated with
TNFa. siRNA mediated knockdown of NOTCH1 impaired
expression from the YKL40 promoter (Figure 6C, upper panel).
We have demonstrated that nuclear P65, regulated by NOTCH1,
activates YKL40 expression in response to TNFa. siRNA mediated
knockdown of P65 also impaired expression from the YKL40

Figure 7. NOTCH1 expression is upregulated in HCV patients.
Total RNA was isolated from liver biopsies obtained from 10 chronic
HCV patients, 10 alcoholic hepatitis patients, 10 NASH patients and 10
normal donor livers (control). Expression of NOTCH1 was determined by
Q-PCR. The DDCT value was calculated by normalizing the threshold
(CT) values with GAPDH expression and expression of NOTCH1 in
controls. The ‘*’ represents p value,0.01 obtained by a two-tailed t test.
Error bars represent SD.
doi:10.1371/journal.pone.0050826.g007

translocated into the nucleus and quantification showed more than
three fold nuclear abundance of P65 compared to the untreated
cells (Figure 5C). Next, the HEPG2 cells were transfected with
either scrambled siRNA or siRNA specific for human NOTCH1
and subjected to TNFa treatment. Immunostaining with antiNotch1 showed more than four fold knockdown of NOTCH1 by
siRNA (Figure S2B, C). Knockdown of NOTCH1 resulted in
impairment of TNFa mediated nuclear translocation of P65 by
two fold (Figures 5D and E). TNFa mediated nuclear localization
of P65 in cells transfected with scrambled siRNA was not affected.
This finding indicates that NOTCH1 acts as an upstream
regulatory factor and controls TNFa mediated nuclear translocation of P65.

miRNA-449a Regulates YKL40 Expression by Modulating
NOTCH1 Expression
Genomewide microarray analysis in our laboratory followed by
miRNA gene expression analysis showed that miRNA-449a is
downregulated more than two fold in HCV patients compared to
non-HCV liver diseases and normals (Figure 1A). Computational
target prediction of miRNA-449a using Targetscan (Targetscan.org) identified NOTCH1 to be a putative target for translational
silencing. To test this, hepatocytes were transfected with either
PLOS ONE | www.plosone.org
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promoter (Figure 6C, upper panel). Western blot analysis using
anti-YKL40 showed downregulation of YKL40 by expression of
miRNA-449a or siRNA mediated knockdown of NOTCH1 or P65
in hepatocytes (Figure 6C, lower panels). qPCR analysis also
confirmed downregulation of YKL40 by miRNA-449a (Figure S3).
Immunoblot analysis using anti-NOTCH1 demonstrated that
expression of miRNA-449a resulted in downregulation of
NOTCH1. Since, P65 is a downstream factor for NOTCH1,
knockdown of P65 did not affect its expression (Figure 6C, lower
panels). This suggests that miRNA-449a regulates expression of
YKL40 by modulating the NOTCH1 signaling pathway.
To further determine if TNFa mediated activation of YKL40 is
regulated by miRNA-449a, hepatocytes were transfected with
either a control vector or vector expressing miRNA-449a along
with an YKL40-driven luciferase reporter construct (23000 bp)
and cells were treated with or without TNFa. In the cells
expressing the empty vector, TNFa induced expression from the
YKL40 promoter (Figure 6D). However, in presence of miRNA449a this TNFa mediated upregulation of YKL40 was impaired.

roles in hepatic fibrosis [27,28]. Differential modulation of CEBPa
has been shown in HCC patients [17,29]. Our analysis on the
regulation of the inflammatory biomarker YKL40 expression at the
transcriptional level provides new insight into role of components
of the NOTCH and NFKB signaling pathways in HCV induced
hepatic fibrosis and HCC. It is of interest that HCV core protein
NS3 can activate the NOTCH signaling pathway resulting in
development of HCV-induced HCC [30]. Activation of NOTCH
signaling also promotes TGFb1 induced epithelial-mesenchymal
transition, an initial step in the development of fibrosis, by directly
interacting with the transcriptional machinery [31,32,33]. Modulation of both NOTCH1 and NFKB pathways have also been
implicated in several cancers including HCC [34,35,36,37].
In addition to demonstrating the interaction of NOTCH,
CEBPa and NFKB pathways in YKL40 expression, we determined
an important role for modulation of miRNA by HCV. The
understanding of the complex role of miRNAs in the various
physiological and pathological processes is still emerging. miRNAs
have been implicated in regulation of pro-inflammatory cytokines,
anti-inflammatory cytokines, and interferons [38]. miRNA-21 has
been shown to regulate chronic rejection and has been implicated
in the development of fibrosis following liver transplantation
[39,40]. miRNA-21 modulates resident fibroblasts, epithelial cells
and lymphocytes to produce pro-fibrotic cytokines resulting in
deposition of ECM components [39,41]. It has been shown that
several liver specific miRNAs including miRNA-122, miRNA-148,
miRNA-194 are sensitive biomarkers for hepatocyte injury and
rejection after liver transplantation [42]. In this study we identified
a novel miRNA (miRNA-449a) that is modulated in HCV
infection. Further, we have shown that miRNA-449a regulates
HCV induced inflammatory responses (YKL40) implicated in
allograft liver fibrosis.
Previous studies in our laboratory have demonstrated an
upregulation of autoimmune Th17 inflammatory cascade leading
to liver fibrosis in HCV infection, particularly in recurrent HCV
following orthotopic liver transplantation [43]. Viral modulations
of miRNA have been well known to influence transcriptional
regulation in T cell responses, inflammation and fibrosis [44].
Although suggested in literature, a direct effect of HCV mediated
modulation of cellular inflammatory responses and fibrosis is yet to
be determined. In our current study using promoter analyses
techniques we provide direct evidence for the role of miRNA449a, which is down regulated in HCV infection (Figure 1), in the
upregulation pro-inflammatory YKL40 fibrotic cascade. miRNA449a has been implicated transcriptional dysregulation affecting
cell proliferation in several human diseases including cancers
[45,46]. In vitro studies have also shown that miRNA-449a can
arrest cell proliferation and induce apoptosis [46,47]. Thus, HCV
induced down regulation of miRNA-449a in human livers can
upregulate transcriptional factors leading to increased inflammatory response; promoting cell proliferation that can result in HCC.
We have also demonstrated by in vitro analysis that miRNA449a regulates TNFa mediated induction of YKL40 by targeting
components of the NOTCH signaling pathway (NOTCH1)
(Figure 6). We have shown for the first time in human hepatocytes
that miRNA-449a targets NOTCH1 for translational silencing.
Studies have shown that miRNA-34a is downregulated in patients
with chronic hypoxia kidney diseases and promotes epithelialmesenchymal transition by targeting components of the NOTCH
signaling pathway [48]. In HCV infected patients expression of
miRNA-449a was significantly downregulated (Figure 1A). In
consistence with our in vitro results, in the same HCV patients
downregulation of miRNA-449a was accompanied by significant
upregulation of NOTCH1 (Figure 7). Thus, results obtained from

NOTCH1 Expression is Upregulated in HCV Patients
To determine whether downregulation of miRNA-449a in
HCV infection is accompanied by upregulation of its target
NOTCH1, biopsies were obtained from 10 chronic HCV patients,
10 alcoholic hepatitis patients, 10 NASH patients and 10 control
normal donor livers at the time of liver transplant. Total RNA
isolation followed by qPCR demonstrated NOTCH1 to be
significantly upregulated in livers obtained from HCV patients.
However, no significant difference in the expression of NOTCH1
was observed in alcoholic hepatitis patients, NASH patients and
normal livers (Figure 7). Based on our in-vitro results obtained with
hepatocytes, upregulation of NOTCH1 and YKL40 (Figure 1) in
HCV patients can be attributed to downregulation of miRNA449a.

Discussion
YKL40, a member of the mammalian chitinase-like protein, has
been shown to be elevated in patients with chronic liver diseases
with fibrosis and cirrhosis (Figure 1) [5,6]. In chronic liver disease
patients, YKL40 expression has been shown to have a strong
correlation with degree of fibrosis progression, extracellular matrix
(ECM) synthesis, and serves an early indicator of liver fibrosis
[23,24]. In HCC patients, YKL40 expression is highly elevated in
both serum and liver tissue [25]. Here we demonstrate that YKL40
expression in human livers is regulated by co-operative action of
several promoter-bound transcription factors. By computational
analysis and subsequent in vitro studies we have defined putative
binding sites for NFKB subunit P65 and CEBPa in the YKL40
promoter (Figure 3A). The NFKB pathway plays an important
role in liver fibrosis, as its activation in hepatocytes can lead to
activation of surrounding tissue macrophages and thus leading to
fibrosis [26]. We demonstrated that TNFa mediated YKL40
expression is regulated by P65, a component of the NOTCH/
NFKB signaling pathway (Figures 2 and 3). Additionally our study
demonstrates that NOTCH1 is essential for nuclear retention of
P65 in human liver cells (Figure 5). Studies in animal models have
shown that knockdown of NOTCH1 resulted in impairment of
DNA binding and transcriptional activation ability of P65 and
impacted dendritic cell differentiation [12]. We have shown for the
first time that the NFKB subunit P65 cooperates with CEBPa to
regulate expression of YKL40 through direct DNA binding in
hepatocytes (Figures 3 and 4). Several studies have shown that
CEBPa regulates activation of hepatic stellate cells which play key
PLOS ONE | www.plosone.org
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patient samples and our in vitro analysis using hepatocytes indicate
that upregulation of NOTCH1 resulting from downregulation of
miRNA-449a stabilizes nuclear P65 to activate YKL40 expression
in patients with HCV mediated hepatic fibrosis (Figure 1). The
increased expression of YKL40 in patients with HCV mediated
liver fibrosis [5,6] can be attributed to this novel pathway
(Figure 8). Since, YKL40 is elevated in patients with multiple
liver diseases (Figure 1B); it is likely that other parallel pathways for
its transcriptional regulation may exist in non-HCV mediated liver
fibrosis.
Taken together our results provide new insight into the
mechanisms by which miRNAs mediate changes in the inflammatory process by modulating components of the transcriptional machinery. The results from this study should assist in the
development of novel strategies for identifying non-invasive
biomarkers that can prognosticate patients and monitor those at
increased risk for development of cirrhosis and HCC following
HCV infection.

Figure S2 siRNA mediated knockdown of NOTCH1. A.
Hepatocytes were transfected with either non-specific siRNA or
siRNA specific for NOTCH1 and treated with TNFa. Lysates
were subjected to immunoblotting with anti-NOTCH1. B.
HEPG2 cells were transfected with either non-specific siRNA or
siRNA specific for NOTCH1, treated with TNFa and immunostained with anti-NOTCH1. C. Quantification of the NOTCH1
immunostaining signal in HEPG2 cells (S2B). The numbers
represent the average fluorescence intensity of P65 (n = 100).
(TIF)
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